{
    "clinical_study": {
        "@rank": "121198", 
        "arm_group": {
            "arm_group_label": "64Cu-DOTA-AE105 PET", 
            "arm_group_type": "Experimental", 
            "description": "One injection of 64-Cu-DOTA-AE105 (app. 200 Mbq IV) followed by 3 PET scans 1,3 and 24 hours post injection"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for\n      PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential\n      of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and\n      less aggressive tumors. This is a first in human study to test the radiotracer in cancer\n      patients. The biodistribution and tumor uptake will be evaluated by repeated PET imaging\n      (1,3 and 24 hours post injection)."
        }, 
        "brief_title": "Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Prostate Cancer", 
            "Urinary Bladder Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Breast Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for\n      PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential\n      of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and\n      less aggressive tumors. This is a first in human study to test the radiotracer in cancer\n      patients. The biodistribution and tumor uptake will be evaluated by repeated PET imaging\n      (1,3 and 24 hours post injection). The primary end points are  Biodistribution and dosimetry\n      of 64Cu-DOTA-AE105. In addition, the quantitative uptake of 64Cu-DOTA-AE105 in tumors and\n      expression of uPAR in tumor tissue obtained by surgery or biopsies (either 14 days before\n      (only biopsies) or after the PET scans) will be compared to validate the image-derived data\n      on UPAR expression"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  clinical diagnosis of cancer of prostate, breast or urinary bladder\n\n          -  capable of understanding and giving full informed consent\n\n        Exclusion Criteria:\n\n          -  pregnancy\n\n          -  lactation\n\n          -  contraindication for the use of intravenous CT contrast-agencies\n\n          -  claustrophobia\n\n          -  other current/or former diagnosed cancers, except non melanoma skin cancer or\n             carcinoma in situ cervicis uteri"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139371", 
            "org_study_id": "2013-574"
        }, 
        "intervention": {
            "arm_group_label": "64Cu-DOTA-AE105 PET", 
            "description": "One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection", 
            "intervention_name": "Injection of 64Cu-DOTA-AE105", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Plasminogen"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Positron Emission Tomography", 
            "Uroplasminogen Plasminogen Activator Receptor", 
            "Breast cancer", 
            "Prostate cancer", 
            "Urinary bladder cancer", 
            "Biodistribution", 
            "Radiation exposure"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "contact": {
                "email": "dskovgaard@dadlnet.dk", 
                "last_name": "Dorthe Skovgaard, MD, PhD", 
                "phone": "+4561274706"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "2100"
                }, 
                "name": "Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet"
            }, 
            "investigator": {
                "last_name": "Dorthe Skovgaard, MD, Phd", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "1", 
        "official_title": "64Cu-DOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor) for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Man.", 
        "overall_contact": {
            "email": "dskovgaard@dadlnet.dk", 
            "last_name": "Dorthe Skovgaard, MD, Phd", 
            "phone": "+4561274706"
        }, 
        "overall_official": {
            "affiliation": "Rigshospitalet, Denmark", 
            "last_name": "Dorthe Skovgaard, MD, Phd", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The patients will be PET scanned 1, 3 and 24 hours post injection of the radiotracer 64Cu-DOTA-AE105. These different timepoints will be used for assessment of biodistribution", 
                "measure": "Biodistribution", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "The patients will be PET scanned 1, 3 and 24 hours post injection of the radiotracer 64Cu-DOTA-AE105. These different timepoints will be used for  calculation of dosimetry", 
                "measure": "Dosimetry", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "reference": {
            "PMID": "22213823", 
            "citation": "Persson M, Madsen J, \u00d8stergaard S, Jensen MM, J\u00f8rgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med. 2012 Jan;53(1):138-45. doi: 10.2967/jnumed.110.083386."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139371"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rigshospitalet, Denmark", 
            "investigator_full_name": "Dorthe Skovgaard", 
            "investigator_title": "MD, Phd", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Tumor uptake of 64Cu-DOTA-AE105 will be compared with expression of uPAR (using immunohistochemistry and ELISA) in tumor tissue obtained from biopsies/or operative removal of the tumors.", 
                "measure": "Expression of UPAR in tumor tissue", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "The patients will be PET scanned 1, 3 and 24 hours post injection of the radiotracer 64Cu-DOTA-AE105. These different timepoints will be used for assessment of tumor uptake of 64Cu-DOTA-AE105 will be assessed by PET scans 1, 3 and 24 hours post injection", 
                "measure": "Quantitative uptake of UPAR in tumor tissue", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Rigshospitalet, Denmark", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigshospitalet, Denmark", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}